Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD
1.04
-0.05 (-4.59%)
At close: Sep 22, 2023, 4:00 PM
1.06
+0.02 (1.92%)
After-hours: Sep 22, 2023, 5:24 PM EDT
-4.59%
Market Cap 39.47M
Revenue (ttm) 6.78M
Net Income (ttm) -76.79M
Shares Out 37.95M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 280,628
Open 1.10
Previous Close 1.09
Day's Range 1.02 - 1.12
52-Week Range 1.01 - 2.03
Beta 0.86
Analysts Buy
Price Target 5.00 (+380.77%)
Earnings Date Nov 9, 2023

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 94
Stock Exchange NASDAQ
Ticker Symbol BOLT
Full Company Profile

Financial Performance

In 2022, BOLT's revenue was $5.73 million, an increase of 354.68% compared to the previous year's $1.26 million. Losses were -$88.10 million, -10.64% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 380.77% from the latest price.

Price Target
$5.0
(380.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of can...

11 days ago - GlobeNewsWire

Bolt Biotherapeutics to Participate in September Investor Conferences

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...

18 days ago - GlobeNewsWire

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

6 weeks ago - GlobeNewsWire

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

7 weeks ago - GlobeNewsWire

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

7 weeks ago - GlobeNewsWire

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be prese...

4 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cance...

4 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials

5 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of can...

6 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the tre...

6 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment...

6 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

7 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present at February Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

8 months ago - GlobeNewsWire

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

10 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

1 year ago - GlobeNewsWire

Bolt, Orion-E to build solar plants in Brazil for about $630 million

Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive ...

1 year ago - Reuters

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

–   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022

1 year ago - GlobeNewsWire

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

REDWOOD CITY, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising...

1 year ago - Benzinga

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine ...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the ta...

2 years ago - GlobeNewsWire